Shots:
- OS Therapies has reported data from 2 studies assessing OST-HER2 with palliative radiation to prevent or delay amputation in dogs with unresected appendicular osteosarcoma
- Unpublished data showed tumor arrest, delayed metastases, & >500-day survival in 5/15 dogs while data published Molecular Therapy, showed early immune response from the 1st dose, with short-term survivors with defective immune response improving after 2nd/3rd doses, supporting recurrent dosing; data show OST-HER2 potential for human use
- Company will submit data to the USDA for conditional approval of its patented OST-HER2 manufacturing process, expecting launch by 2025 end; pivotal trial is planned to seek full approval in 2026
Ref: Businesswire | Image: OS Therapies
Related News:- Spirited Paw Launches Calm Chewable Wafers for Dogs and Cats
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
